# Capecitabine and Oxaliplatin With or Without Cetuximab in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery

> **NCT00227734** · PHASE2 · COMPLETED · sponsor: **Swiss Cancer Institute** · enrollment: 74 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** capecitabine and oxaliplatin + cetuximab
- **DRUG:** capecitabine and oxaliplatin

## Key facts

- **NCT ID:** NCT00227734
- **Lead sponsor:** Swiss Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** 2005-10
- **Final completion:** 2006-02
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2012-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00227734

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00227734, "Capecitabine and Oxaliplatin With or Without Cetuximab in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00227734. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*